Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lleo

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Journal of Hepatology|February 15, 2022
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryLaura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2025
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated CirrhosisPinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, et al.
Nature Genetics|July 20, 2010
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosisXiangdong Liu, Pietro Invernizzi, Yue Lu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 23, 2024
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary CholangitisAntonio De Vincentis, Javier Ampuero, Francesca Terracciani, et al.
JHEP Reports : Innovation in Hepatology|July 21, 2025
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-worldFrancesca Terracciani, Antonio De Vincentis, Daphne D'Amato, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Journal of Hepatology|February 15, 2022
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryLaura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2025
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated CirrhosisPinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, et al.
Nature Genetics|July 20, 2010
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosisXiangdong Liu, Pietro Invernizzi, Yue Lu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 23, 2024
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary CholangitisAntonio De Vincentis, Javier Ampuero, Francesca Terracciani, et al.
JHEP Reports : Innovation in Hepatology|July 21, 2025
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-worldFrancesca Terracciani, Antonio De Vincentis, Daphne D'Amato, et al.
Pageof 21